KUR 101
Alternative Names: KUR-101Latest Information Update: 28 Mar 2025
At a glance
- Originator Columbia University
- Developer ATAI Life Sciences; Kures
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Small molecules
- Mechanism of Action Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Opioid-related disorders
- No development reported Acute pain
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Acute pain(In volunteers) in New Zealand (PO)
- 23 Dec 2022 Safety and efficacy data from a phase I trial in Acute pain released by ATAI Life sciences
- 14 Oct 2022 Phase-I clinical trials in Opioid-related disorders in USA (PO) ,prior to October 2022 (ATAI Life sciences pipeline, October 2022)